Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Preparation of crystalline forms of dihydropyrazolopyrimidinone
US9388186B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9388186-B2 |
| Application number | US-201414199653-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2014 |
| Priority date | Sep 15, 2009 |
| Publication date | Jul 12, 2016 |
| Grant date | Jul 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.
First claim
Opening claim text (preview).
What is claimed is: 1. A novel crystalline 2-allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one hemihydrate which is characterized by an x-ray powder diffraction pattern, collected using copper Kα radiation, corresponding to d-spacings of 10.66, 5.30 and 4.18 angstroms. 2. The novel crystalline hemihydrate of claim 1 which is further characterized by d-spacings of 9.11, 8.80 and 3.54 angstroms. 3. The novel crystalline hemihydrate of claim 2 which is further characterized by d-spacings of 18.22, 3.09 and 3.02 angstroms. 4. The novel crystalline hemihydrate of claim 1 which is characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 116.6, 52.4, 55.0 and 31.7 p.p.m. 5. The novel crystalline hemihydrate of claim 4 which is further characterized by signals at 145.0, 154.8, 160.1, and 169.4 p.p.m. 6. A pharmaceutical composition comprising the crystalline hemihydrate of claim 1 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
containing further heterocyclic rings · CPC title
Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9388186B2 cover?
- The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).